Mergers & Acquisitions ·
Jasper raises $132M in private placement as it completes acquisition of Kira Pharmaceuticals
JSPRJasper Therapeutics, Inc.
Jasper Therapeutics, Inc. filed an amendment to its Current Report on Form 8-K/A to include the audited financial statements of Kira Pharmaceuticals and unaudited pro forma condensed combined financial information following the completion of Jasper's acquisition of Kira on July 16, 2026. The transaction involved Kira merging into a wholly owned subsidiary of Jasper, with Kira shareholders receiving shares of Jasper common stock and non-voting convertible preferred stock. Concurrently, Jasper completed a private placement financing through the sale of approximately 4.7 million shares of non-voting convertible preferred stock for gross proceeds of $132 million. The pro forma financials reflect the merger, the concurrent private placement, the distribution of contingent value rights, and the Mirador License Agreement. Jasper Therapeutics, Inc. operates in the biotechnology industry, focusing on the discovery and development of novel therapeutics.